SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

• Ana Fernández Montes ^[1] ; Vicente Alonso ^[2] ; Enrique Aranda ^[3] ; Elena Élez ^[7] ; Pilar García Alfonso ^[4] ; Cristina Grávalos ^[5] ; Joan Maurel ^[8] ; Ruth Vera ^[6] ; Rosario Vidal ^[9] ; Jorge Aparicio ^[10]
  1. [1] Complexo Hospitalario Universitario da Coruña

     Complexo Hospitalario Universitario da Coruña

     A Coruña, España

     
  2. [2] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  3. [3] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  4. [4] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  5. [5] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  6. [6] Hospital Universitario de Navarra

     Hospital Universitario de Navarra

     Pamplona, España

     
  7. [7] Servicio de Oncología Médica, Hospital Universitario Vall D’Hebron, Barcelona, España
  8. [8] Servicio de Oncología Médica, Hospital Clínic, Barcelona, España
  9. [9] Servicio de Oncología Médica, Complejo Asistencial Universitario, Salamanca, España
  10. [10] Servicio de Oncología Médica, Hospital Universitari i Politècnic la Fe, Valencia, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 9 (September), 2023, págs. 2718-2731
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Colorectal cancer (CRC) is the second leading cause of cancer deaths in Spain. Metastatic disease is present in 15–30% of patients at diagnosis and up to 20–50% of those with initially localized disease eventually develop metastases. Recent scientific knowledge acknowledges that this is a clinically and biologically heterogeneous disease. As treatment options increase, prognosis for individuals with metastatic disease has steadily improved over recent decades. Disease management should be discussed among experienced, multidisciplinary teams to select the most appropriate systemic treatment (chemotherapy and targeted agents) and to integrate surgical or ablative procedures, when indicated. Clinical presentation, tumor sidedness, molecular profile, disease extension, comorbidities, and patient preferences are key factors when designing a customized treatment plan. These guidelines seek to provide succinct recommendations for managing metastatic CRC.